3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Lung Neoplasms
7
Prostatic Neoplasms
6
Hematopoietic and Lymphatic System Neoplasm
6
Hematologic Neoplasms
6
Colorectal Neoplasms
5
Breast Neoplasms
5
Anatomic Stage I Breast Cancer AJCC v8
5
Pancreatic Neoplasms
3
Neoplasms
3
Malignant Solid Neoplasm
3
Leukemia, Myeloid, Acute
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Ovarian Neoplasms
2
Mouth Neoplasms
2
Melanoma
2
Head and Neck Carcinoma
2
Glioma
2
Carcinoma, Renal Cell
2
Carcinoma
2
COVID-19
2
Uveal Melanoma
1
Urologic Neoplasms
1
Urologic Diseases
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Tonsillar Neoplasms
1
Tongue Neoplasms
1
Teratoma
1
Stomatitis
1
Interventions
Gemcitabine
29
pembrolizumab
20
Cisplatin
20
Magnetic Resonance Spectroscopy
17
Specimen Handling
16
Mitomycin
10
enfortumab vedotin
9
durvalumab
9
Cystoscopy
9
avelumab
8
Nivolumab
8
Fluorouracil
8
Carboplatin
8
Radiation
7
Cystectomy
6
atezolizumab
5
Transurethral Resection of Bladder
5
Radiotherapy
5
Mitozytrex
5
Docetaxel
5
Biopsy
5
tremelimumab
4
sacituzumab govitecan
4
erdafitinib
4
dehydroftorafur
4
Platinum
4
Immunoglobulin G
4
Disulfides
4
1,2-diaminocyclohexaneplatinum II citrate
4
disitamab vedotin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
Practice Guidelines as Topic
×
90 days
×
Clear all
NCT07087860
2026-05-08
RECIPE-B1
Mayo Clinic
Phase 2
Recruiting
70 enrolled